Cystic Fibrosis Foundation backs Israeli biotech with $13m to develop inhaled drug - Pharmaceutical Technology

SpliSense is currently conducting a Phase IIb trial with its antisense oligonucleotide therapy. SpliSense is currently conducting a Phase IIb trial with its antisense oligonucleotide therapy. There are close to 40,000 children and adults living with cystic fibrosis in the US. Credit: HobbitArt/Shutterstock.com. The Cystic Fibrosis Foundation has supplied $13m of funding to SpliSense, helping the biotech continue development of its inhaled drug candidate designed to treat the disease. SpliSense’s SPL84, an antisense oligonucleotide (ASO) therapy, is being developed for patients with cystic fibrosis carrying the 3849+10kb C→T mutation. LOA and PTSR Model 4D-710 in Cystic Fibrosis Reports LOA…

Source: Pharmaceutical Technology